← Leaderboards
Kenneth G Payie
Agenebio, Inc.
$2,446,400
Attributed
$2,446,400
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2024–25$2M$1.5M$1M$500K$0
'24
'25
Funding mix
By agency
NIH$2,446,400 · 1
By mechanism
U01$2,446,400 · 1
Top collaborators
No co-investigators on record.
Most similar at Agenebio, Inc.
Same institution · by research overlap
- Sharon Rosenzweig-Lipson$9,435,769
Others in their field
Other Rising Stars on “Alzheimer&Apos”
- Kjetil Bjornevik · Harvard University D/B/A Harvard School Of Public Health$3,280,861
- Yanling Wang · Rush University Medical Center$2,986,919
- William G Mantyh · University Of Minnesota$2,961,521
- Allison Mercedes Caban-Holt · University Of Miami School Of Medicine$2,611,182
- Brian Stephen Appleby · Cleveland Clinic Lerner Com-Cwru$2,482,260
- Noah Ray Johnson · University Of Colorado Denver$2,282,487
Research focus
Alzheimer&AposIn VitroClinical ResearchGamma-Aminobutyric AcidCaregiversHippocampusAnti-Epileptic AgentsAge-Associated Memory ImpairmentBrain DysfunctionFormulationElderlyChronicClinical DevelopmentAdvanced DevelopmentAcuteCoupledAreaDementia RiskDosage FormsDoseCanis FamiliarisAge RelatedHigh RiskIn Vivo
Grant awards (3)
Preclinical and early clinical development of a GABA-A a5 PAM$1,078,000
U01 · FY2025 · AG · contact PI
Preclinical and early clinical development of a GABA-A a5 PAM$268,400
U01 · FY2025 · AG · contact PI
Preclinical and early clinical development of a GABA-A a5 PAM$1,100,000
U01 · FY2024 · AG · contact PI